

Importance of human breast milk in premature infant

Simonetta Costa, Francesca Serrao, Chiara Tirone, Eloisa Tiberi, Mirta Corsello, Francesca Priolo, Milena Tana, Francesca Paola Fusco, Simonetta Frezza, Giovanni Vento

UOC Neonatologia, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

Simonetta Costa and Francesca Serrao equally contributed to this article.

Corresponding Author: Giovanni Vento, MD; e-mail: giovanni.vento@unicatt.it

ABSTRACT

Human breast milk (HBM) is considered the optimum feeding for infant nutrition. The specific composition and unique properties make HBM appropriate not only for the term but also for preterm infants. HBM feeding confers protection to preterm infants against the most serious morbidities of prematurity and decreases mortality in a dose-dependent manner. We performed a literature review, aiming to provide an update on the available evidence regarding the importance and the advantages of HBM on preterm infants' health. Our findings confirmed the several health benefits in preterm infants, including the improvement of neurodevelopmental outcomes and the protection against necrotizing enterocolitis and infections. Many more investigations will be necessary to understand the mechanisms underlying the beneficial association of HBM with neurodevelopmental outcomes and to confirm the beneficial effects of HBM on bronchopulmonary dysplasia. Based on the current evidence on the health benefit of HBM feeding, promotion and support of lactation since the immediate post-delivery should be considered a priority in preterm infants' care.

KEYWORDS

HUMAN BREAST MILK
DONOR HUMAN MILK
PRETERM INFANTS
NUTRITIONAL
BIOACTIVE FACTORS
NEURODEVELOPMENT
HEALTH BENEFITS

INTRODUCTION

Human breast milk (HBM) has been shown to be the optimum feeding for infant nutrition^{1,2}. Its specific composition makes HBM appropriate not only for the term but also for preterm infants³⁻⁸. Feeding preterm infants with HBM confers protection against the most serious morbidities of prematurity such as necrotizing enterocolitis (NEC) and sepsis⁹⁻¹⁴, retinopathy of prematurity (ROP)¹⁵⁻¹⁷, bronchopulmonary dysplasia (BPD)¹⁸⁻²⁰, and decreases mortality in a dose-dependent manner¹⁰. HBM feeding improves long-term neurocognitive outcomes²¹⁻²³ and confers beneficial effects against obesity²⁴.

We conducted a narrative review to provide an update on the available evidence regarding the importance and the advantages of HBM on preterm infants' health. We searched the PubMed database for articles relating to HBM using specific keywords such as breastmilk, humanmilk, nutritional, macronutrients, micronutrient, microbiome, bioactive factors, expressed and donor human milk, neurodevelopment, bronchopulmonary dysplasia, necrotizing enterocolitis. Preference was given to the more recent published sources (within 5 years), taking also into account the milestones. We included randomized controlled trials (RCTs), cohort studies, systematic reviews, and meta-analyses as well as preclinical studies.

HUMAN BREAST MILK COMPOSITION

MACRONUTRIENTS

HBM includes many nutritional elements such as fat, carbohydrates, proteins, and HM oligosaccharides (HMOs). They all play a central role in infant growth²⁵. HM is composed of water (87%-88%), and solid components such as fat (3.8%), protein (1.0%), and carbohydrates (7%). It has a specific gravity of 1.030 and an osmolarity of approximately 286 mOsm/L²⁶.

Usually, mature HMB contains 65-70 kcal per 100 mL of energy, and about 50% and 40% of the total energy of the milk is provided, respectively, from fat and lactose²⁷.

Anyhow, HBM composition fluctuates over time, adjusting itself to the child's necessities during growth²⁸; it even depends on environmental aspects, maternal health and diet, mammary gland physiology²⁶, on prematurity, if it is foremilk or hindmilk, and if it is colostrum, transitional milk, or mature milk²⁹. Colostrum indeed is high in protein (10%) and low in fat, and is relatively rich in immune-protective components, such as immunoglobulin A (IgA) and lactoferrin, which help prevent neonatal infections.

Carbohydrates

Carbohydrates are the major macronutrients in HMB and play a crucial role in infant nutrition since they are important from birth for the functionality of the gastrointestinal tract and for the preservation of the intestinal microbiota²⁶.

Lactose is the most abundant nutrient and the primary carbohydrate component in HBM, it is easily digested by nearly all babies³⁰. However, enzymes' deficiency can induce several symptoms, such as lactose intolerance or malabsorption. Contrary to protein and fat, colostrum has moderately constant lactose over time^{28,31}. The nutritional role of free glucose and other glucose metabolites in human milk is marginal because their levels are low.

The second substantial component, reaching nearly 20%, of carbohydrates in HBM is highly complex HMOs. They have a concentration of 12-14 g/L in mature milk and >20 g/L in colostrum³². On the contrary of lactose, which is easily digested, HMOs have limited digestion and they get into the colon in an unbroken form⁶. In early stages after birth, HMOs have an important role as prebiotics, stimulating the growth of certain strains of helpful bacteria, such as *Bifidobacterium infantis*, and defending the newborn from colonization by pathogenic bacteria producing short-chain fatty acids that can preclude,

decreasing the intestinal pH, the growth of unhealthy gut microbiota³³. HMOs can even inhibit neonatal diarrhea and respiratory tract infections^{34,35}. Moreover some HMOs seem to be involved, as a second role, in regulating direct immune responses.

Proteins

Proteins are an important component of HBM as they are involved in cell regulation systems and they are crucial for growth, development and functioning of the human body.

Protein concentration at birth is about 14-16 g/L, but decreases to 8-10 g/L after 3-4 months of birth and further decreases to 7-8 g/L after 6 months^{28,36}. It is not considerably influenced by maternal diet but increases with maternal body weight for height²⁷.

HBM includes over 400 different proteins with multiple functions and they can be divided into three groups: caseins, whey and mucin proteins^{26,37}.

Casein of HBM occurs as alpha, beta, gamma and kappa casein and is more likely digested in the form of looser micelles and softer curd by an enzyme called carboxypeptidase, which controls intestinal motility and helps in calcium absorption.

The whey/casein ratio varies according to the time of HBM. The whey/casein ratio in HBM fluctuates between 70/30 and 80/20 in early lactation and decreases to 50/50 in late lactation²⁸. Typical whey proteins of HBM are alpha-lactalbumin, which constitutes 40% of the whey protein, lactoferrin, and secretory IgA³. Alpha-lactalbumin support the mammary glands in producing lactose, helps providing essential amino acids and absorption of minerals and trace elements in infants and has antibacterial properties³⁷. Lactoferrin and lysozyme stop the spread of potentially harmful bacteria, and IgA protects gut mucosa and kills bacteria²⁷.

Lastly, nonprotein nitrogen, such as urea, creatinine, nucleotides, free amino acids and peptides, consists of about 20%-25% of HBM protein. Nearly 50% of this is urea nitrogen, which is used to produce nonessential amino acids³⁸.

Fat

Fat is the second largest macronutrient in HBM and its concentration is essential for infant growth, as a nutrient supply (nearly 40%-55% of the total energy of HBM) and for the development of the central nervous system. In addition, HBM fat is a carrier of taste and aroma^{28,39}. It is tightly associated with maternal diet and weight gain during pregnancy; moreover, there are regional differences in food intake²⁸.

Colostrum fat concentration is about 15-20 g/L,

but this quantity gradually increases, and mature milk contains almost 40 g/L. Its levels are 2-3 times higher in hindmilk than in foremilk⁴⁰.

Breast milk includes over 200 fatty acids; however, many of these are present in very low quantities, with others predominant.

The major lipid fraction is triglycerides (about 95%-98% of total lipids). Approximately half of HBM fatty acids are saturated fatty acids, with 23% palmitic acid (C16:0) in total fatty acids. The oleic acid (18:1w9), a monounsaturated fatty acid, is one with the highest percentage (36%) in milk. HBM also contains two essential fatty acids, linoleic acid (LA) (C18:2w6) and alpha-linolenic acid (ALA) (C18:3w3), respectively 15% and 0.35%³⁶ involved, as precursors, in the synthesis of arachidonic acid (AA), the former, and eicosapentaenoic acid (EPA) further converted to docosahexaenoic acid (DHA), the latter. However, this phenomenon is limited in the fetus and neonate as a result of the premature enzyme activity. Therefore, the required amounts of AA and DHA are provided from the mother during pregnancy or from HBM shortly after birth²⁸. In addition, LA and alpha-linolenic acid are important for inflammatory process, immune function, and infant growth.

Even short-chain fatty acids (SCFA) in HBM are an essential source of energy⁴¹ and they are important for the development of the gastrointestinal tract⁴².

Sphingomyelins, included in the HBM fat globule membrane, are in particular crucial for central nervous system myelination, and it has been described that they can improve the neurobehavioral development of low-birth weight infants⁴³.

MICRONUTRIENTS

HBM includes also micronutrients – vitamins and minerals – essential for growing and developing of preterm infants. They play a central role on infant neurodevelopment but also on muscular and soft tissues system; they are indispensable for several metabolic processes. Moreover, minerals and vitamins have anti-infection and anti-oxidant effects⁴⁴. Resources required for the maturation of the central nervous system come not only from glucose but also from copper, iron, selenium, zinc. The structuring of the brain depends on lipids, proteins, and folate. Zinc and iodine are necessary for neural cell differentiation; myelination is influenced by cholesterol, vitamin B12, choline, iron, iodine, and copper. Calcium, phosphorus and magnesium are crucial for metabolic resources and for the skeletal and immune systems. An inadequate intake of these micronutrients has

been addressed as a risk factor for neurocognitive impairment and adverse long-term development⁴⁵.

There is a substantial variability in the composition of HBM from one mother to another, concerning micronutrients. These differences are influenced by maternal age, parity, lactation time, behavioral factors, nutritional status, and maternal diet⁴⁶. In any case, HBM does not generally give sufficient amounts of micronutrients, and it must be supplemented, particularly when using a milk bank⁴⁷, since pasteurization and freezing processes alter vitamin functions.

HBM vitamins

Thiamin acts as a coenzyme in the metabolism of carbohydrates and branched-chain amino acids; its deficiency causes infantile beriberi.

Riboflavin (vitamin B2) is involved in energy production and activity of glutathione, a free radical scavenger; its deficiency is responsible for poor growth, impaired iron absorption, dermatologic abnormalities and peripheral neuropathy.

Vitamin B6 acts as a cofactor of numerous enzymatic activities, and plays a role in amino acid metabolism, gluconeogenesis and glycolysis; its deficiency leads to neurological and behavior abnormalities, irritability and seizures.

Vitamin B12 acts as a cofactor in enzymatic reactions, which are essential for folate metabolism and DNA synthesis; its deficiency causes neurologic symptoms and developmental regression.

Folate is necessary for protein, DNA, and RNA biosynthesis. Choline is a precursor of acetylcholine and has also a role in the integrity of cell membranes, lipid and methyl group metabolism, brain development and trans-membranes signaling.

Vitamin C is an antioxidant agent and has also an important role in immunomodulation: augments antibody production, stimulates leukocytes, and synthesis of interferons. Vitamin C is more concentrated in preterm than in term milk.

Vitamin A appropriate concentration in HBM is important for ensuring infant development and for accumulating liver stores needed after weaning.

Vitamin D has an important role in infant bone growth, brain and immune system development.

Vitamin E is an antioxidant agent for the fetus and the newborn and stimulates the development of the immune system. Preterm delivery reduces breast milk concentration.

Vitamin K concentration is very low in HBM, and infants who do not receive at birth a prophylactic dose of Vitamin K, have a risk for hemorrhagic disease.

HBM minerals

Iron is a part of the hemoglobin chain and an essential component of different enzymes. Preterm infants are particularly susceptible to iron deficiency due to its effects on growth and brain development. Iron HBM concentration is very low and independent of maternal diet.

Copper is a cofactor for enzymes involved in cellular respiration, connective tissue synthesis and iron metabolism. Copper concentrations in HBM are not related to the maternal status, but depend on selenium concentrations.

Zinc deficiency in infants results in reduced growth and compromised immune function. Adequate intake of Zinc in preterm infants promotes growth and prevents diarrhea⁴⁸.

Calcium is an important constituent of bone and a messenger in cell-signaling pathways. HBM total calcium increases in the first week and then declines. On the contrary ionized calcium concentration is stable throughout lactation in HBM. Calcium HBM concentration is independent of maternal status and diet. Phosphorus is a component of cell membranes and nucleic acids and is involved in acid-base balance, bone mineralization, energy production and cell signaling. HBM phosphorus concentration increases in the first week and then declines, like calcium.

Magnesium is an important constituent of bone and plays a role in essential metabolic reactions. Its concentrations are not affected by maternal factors.

Iodine is necessary for mental development, infant growth and survival. HBM iodine concentrations are higher in colostrum and after an initial decline, remain stable.

Selenium is a component of many proteins, like antioxidant glutathione peroxidases and deiodinases. HBM selenium concentrations are higher in colostrum than in mature milk.

BIOACTIVE FACTORS

HBM contains a variety of bioactive factors that have a profound role in preterm infant survival and health.

Immunological factors

HBM contains numerous soluble and cellular components with antimicrobial activity, resistant to intestinal proteolysis, which give protection to the premature infant and promote the maturation of the immune system.

HBM provides the only source of IgA for the first 4 weeks of life with the highest concentrations in colostrum and in the HBM of mothers who deliver early²⁷. IgA comprises the first line of antigen-specific immune defense avoiding pathogenic microorganism adherence and penetration into intestinal epithelium.

HBM cytokines (TGF- β , IL-1B, IL-6, I-10, IL-12, TNF- α , IFN- γ , GM-CSF) can determine immune system shaping in the developing gastrointestinal system of the breastfed neonate⁴⁹.

Depending on the phase and stage of lactation, a variety of leukocytes are present in colostrum and mature milk and could. Leucocytes play a role in promoting the development of the neonatal immune response. Macrophages (55-60%) and neutrophils (30-40%) dominate over lymphocytes (5-10%).

HBM-derived macrophages are reported to have phagocytic activity and to secrete immunoregulatory factors. Additionally, milk macrophages have been reported to contain engulfed sIgA, which they could release on contact with bacteria in the gut.

Great interest concerns the presence of bioactive factors in BHM as lactoferrin and lysozymes, responsible for anti-infective and anti-inflammatory pathways giving a great contribution to neonatal immune system development. Lactoferrin has been shown to inhibit microbial adhesion to host cells and has direct cytotoxic effects against bacteria, viruses and fungi; it limits excessive immune responses by blocking many pro-inflammatory cytokines and promote the growth of probiotic bacteria, regulating intestinal homeostasis.

Finally, HBM has been shown to have its own unique microbiome; HBM is one of the main sources of bacteria in the intestine of a primarily breastfed infant. Thus, the HBM microbiota influences the acquisition and establishment of the intestinal microbiome during infancy and is thought to be a major factor involved in innate immunity during early life⁵⁰.

Lipid absorption

The presence in HBM of bile salt stimulated lipase (BSSL) and the specific stereoisomeric structure of the triglycerides allow better absorption of lipids than the formula.

BSSL appears to be a constitutive enzyme of the mammary glands as it is independent of the volume of milk. The characteristics of the enzyme (kinetics, enzymatic concentration, pH optimum, pH stability, and effect of salts biliary) are similar regardless of the duration of pregnancy or lactation. The activity in milk is constant and does not change during the day or according to diet.

BSSL hydrolyzes triglycerides without position specificity, the main products are free fatty acids which are absorbed more rapidly than monoglycerides in the presence of low intraduodenal concentrations of bile salts as in preterm births. This function allows BSSL to complete the hydrolysis of the diglyceride and monoglyceride produced by pancreatic and gastric lipase, respectively.

Another important role of BSSL is to hydrolyze the retinol esters because the efficient absorption of this vitamin requires the previous hydrolysis⁵¹.

Antioxidant capacity

HBM contains numerous components with antioxidant activities, and feeding with exclusive HBM has been associated with a reduced accumulation of oxygen free radicals⁵².

The antioxidants present in milk belong to several categories: 1. Enzymes (catalase, glutathione peroxidase, glutathione reductase); 2. Vitamins (vitamin A, vitamin C, vitamin E, coenzyme Q, β carotene); 3. Binding proteins (lactalbumin, lactoferrin, transferrin); 4. Enzymatic constituents (copper, zinc, selenium); 5. Growth factors (erythropoietin).

The premature newborn is particularly predisposed to the risk of oxidative damage as a consequence of both the increased postnatal production of oxygen radicals and the immaturity of the protective systems in limiting the reactions they induce. The excess production of free radicals is a frequent occurrence in the preterm infant and can be caused by various metabolic conditions, the most important of which are ischemia-reperfusion, phagocytic activation, the arachidonic acid cascade, metabolism of catecholamines, and mitochondrial metabolism⁵³.

Growth factors

HBM contains numerous growth factors acting on the growth, development, functions and maturation of the epithelium, the immune system, the nervous system, and the gastrointestinal tract¹⁻⁷. These bioactive components belong to five categories: 1. Hormones: prolactin, oxytocin, adrenocorticotrophic hormone, thyroid stimulating hormone, thyroxine, cortisol, insulin, erythropoietin; 2. Growth factors: epithelial growth factor (EGF), insulin-like growth factor I (IGF-1), hepatocyte growth factor (HGF), lactoferrin, polyamines; 3. Neuropeptides: neurotensin, somatostatin, intestinal vasoactive peptide (VIP); 4. Anti-inflammatory agents: antioxidant agents, enzymes that catalyze the destruction of inflammatory mediators, antiproliferative agents, anti-inflammatory cytokines; 5. Immunomodulatory agents: nucleotides, secretory IgA, prolactin, cytokines⁵⁴.

STEM CELLS

HBM represents a precious source of stem cells recently under research for possible therapeutic opportunities. HM-derived mesenchymal stem cells have the potential to be “reprogrammed” to generate a wide range of human tissues⁵⁵.

In vitro studies showed the ability to differentiate into adipogenic, chondrogenic, and osteogenic lines, hepatic cells, and pancreatic, nervous, and cardiomyocytic cell lines. It also seems that among stem cells ingested by newborns each day, some can pass from HBM through the neonatal gut and migrate into the brain and other organs; there, they can persist and proliferate as in a micro-chimerism, influencing the development of the involved organs.

The presence of HBM stem cells shows significant potential use in research and medical therapies as a treatment option, especially in neural damage and disorder⁵⁶.

EXPRESSED BREAST MILK AND DONOR HUMAN MILK IN PRETERM INFANTS

Breastfeeding is considered the ideal and preferred feeding for all infants, but in the case of prematurity, when breastfeeding is not possible or difficult, expressed breast milk (EBM) is the best way to provide enteral nutrition.

The process of expressing needs proper expressing equipment and a milk bottle, transferring EBM into containers for storage, refrigerating or freezing, thawing, and warming EBM, and, finally, the delivery of EBM to the infant. HBM can also be hand-expressed. If there is no delay in infants feeding after expressing, there is little to no necessity for storage, compared to the mother who makes a store for later use, requiring long-term freezing. Once refrigeration or freezing is involved in the process, subsequent defrosting and/or rewarming become involved. Each step in this process has the potential for bacterial contamination, and storing and warming may potentially degrade valuable properties of EBM, so mothers must be adequately trained in the expressing process⁵⁷.

Different scientific societies, such as AAP¹ and ESPGHAN¹³ as well as Milan EMBA/ESPGHAN/AAP Joint Meeting Consensus⁵⁸ recommended that a mother's own milk (MOM) should be the first choice in the feeding of preterm infants. When MOM is not available, donor human milk (DHM) should be the alternative, and only when neither MOM nor DHM is available, preterm formula (PF) should be used.

DHM undergoes pasteurization using the Holder process, which requires heating bottles of milk in a water bath at 62.5°C for 30 min followed by rapid cooling. This is the most commonly used method of pasteurization and it is believed a good compromise between microbiological safety and nutritional

and biological quality of HBM. Indeed, heating treatment and storage of HBM reduce anti-infective properties, cellular components, growth factors, and nutrients, which may reduce its health advantages^{59,60}. However, the beneficial effects of pasteurized DHM seem to remain significant, and DHM is greatly preferable to formula milk¹⁴.

Considering the nutritional properties, HBM – and even more so DHM – does not meet the nutritional needs of preterm infants, requiring a specific fortification regimen to optimize growth⁴⁷. HBM fortification is recommended for all preterm infants with birthweight <1800 grams⁴⁷.

HBM fortification allows the addition of proteins, energy, minerals, trace elements, vitamins and electrolytes, to meet the nutritional needs of the preterm infant. Fortification should start with standard fortification and if infant growth is not appropriate, individualized fortification is suitable⁶¹. The standard fortification consists of adding a fixed amount of multi-nutrient fortifier per 100 mL of HBM to achieve the recommended nutrient intake.

Individualized fortification can be targeted or adjustable. Targeted fortification is based on HBM analysis and then adding macronutrients to standard fortification to achieve recommended intakes^{62,63}. Adjustable fortification is based on infant blood urea nitrogen measurements and then protein intake is adjusted based on blood urea nitrogen levels⁶⁴. Both are suitable depending on the individual experience and expertise.

BENEFITS OF BREAST MILK IN PRETERM INFANTS

Role of HBM against infections and necrotizing enterocolitis

Infections are common among preterm infants during their hospital stay⁶⁵. NEC, which affects the gastrointestinal (GI) tract of preterm infants, is together with infections, one of the major causes of morbidity and mortality in neonatal intensive care units (NICU)⁶⁶.

Although the exact pathogenesis of NEC is still debated and under study, it is known that higher HBM intake is associated with lower rates of neonatal NEC, highlighting the protective role of components present in HBM. HBM intake in the first few days of life is associated with reduced infections, morbidity, and mortality in very low birth weight (VLBW) infants^{12,67}, and it has been shown to contain high

concentrations of beneficial immune mediators that provide bacterial and anti-inflammatory protection and stimulate the growth of the GI tract^{50,68}.

The main factors are commensal microbes, HMOs, immunoglobulins, lactoferrin⁶⁹.

The microbiome of HBM is a major source of bacteria in the gut of a predominantly breastfed infant and help shape the newborn gut microbial community⁵⁰. The most commonly reported genera in HBM include *Staphylococcus*, *Streptococcus*, *Lactobacillus*, *Enterococcus*, *Bifidobacterium*, *Propionibacterium*, and the *Enterobacteriaceae* family⁷⁰. Among all, *Bifidobacterium* is the one most strongly associated with reduced risk of NEC. Specifically, *Bifidobacterium longum* in immature human enterocytes induces a reduction in the production of pro-inflammatory mediators IL-8 and IL-6⁷¹.

HMOs are prebiotic substances found in great abundance in HBM and possess several immunomodulatory protective mechanisms on intestinal tissue that shape its integrity⁷².

HMOs possess structures that resemble cell surface glycans targeted by enteric pathogens. This similarity allows HMOs to prevent the adhesion of enteric pathogens, including *Campylobacter jejuni* and *Rotavirus*, to target cells in the intestinal epithelium. In addition, HBM glycans with a sialic acid moiety also can bind pathogenic organisms, including *Escherichia coli* and *Pseudomonas aeruginosa*⁷³.

HMO 2-fucosyllactose has been identified as the most abundant HMO in HBM. A preclinical study in newborn mice showed that supplementation with HMO 2-fucosyllactose reduced the severity of experimental NEC with decreased gene expression of pro-inflammatory cytokines and protected the integrity of the small intestine. In addition, a higher concentration of HMO disialylacto-N-tetraose in HBM has been shown to be associated with a lower risk of developing NEC in infants⁷².

HBM is the only source of secretory IgA (sIgA) in the newborn. They help to preserve an adequate microbiota, promote tolerance and influence the development of the immune system⁷⁴.

Lactoferrin is an iron-binding glycoprotein that is abundant in HBM, with maximum concentrations in colostrum, and preterm milk tends to maintain higher levels of lactoferrin over time. It inhibits microbial adhesion to host cells and has direct cytotoxic effects against pathogens via lactoferricin formation. Concerning inflammation, lactoferricin allows excessive immune responses by blocking many pro-inflammatory cytokines, including IL-1 β , IL-6, TNF- α , and IL-8, and by suppressing free radical activity⁷⁵.

Lactoferrin supplementation in infants has shown promise, and in recent years it has become the subject of many studies to evaluate its role in reducing the rates of NEC and late-onset sepsis in infants⁷⁶.

Still much to be discovered about the multifactorial etiology of NEC, but certain is that HBM components in their collective teamwork, rather than individual roles, protect against NEC.

During the first days after preterm birth, preterm infants may receive DHM or PF due to maternal milk production delay or insufficiency. Several studies^{46,65,77-79} have shown that increased HBM intake, whether MOM or DHM, was associated with reduced risk of infection/NEC. Moreover, breastfed preterm infants have lower rates of intestinal infections than formula-fed babies, mainly due to the anti-infectious properties of HBM^{77,79}.

Beneficial role of HBM in the prevention/treatment of bronchopulmonary dysplasia

BPD is a severe chronic lung illness that affects premature infants. Improved neonatal care, the development of non-invasive ventilation techniques and the use of antenatal steroids have increased the survival of preterm infants, but the incidence of BPD remains high⁸⁰.

Currently, there are several BPD treatment strategies, starting with delivery room management, and encompassing non-invasive mechanical ventilation, steroids, diuretics, bronchodilators, and caffeine. Furthermore, dietary support, infection management, and vasodilators are beneficial as therapy for BPD.

Optimal nutritional support is considered a cornerstone in the prevention/treatment of BPD^{81,82}.

In 2018, a systematic review and meta-analysis on the effects of DHM on BPD was published⁸³. The authors identified 18 studies, of which 7 studies^{9,11,84-88} were RCTs and 11 studies^{19,89-98} were observational. Meta-analysis of 3 RCTs, which reported on the rate of oxygen-dependence at 36 weeks of PMA (BPD36), could not demonstrate that supplementation of MOM with DHM had a significant effect on BPD36 risk, when compared to supplementation with PF. On the other hand, a meta-analysis of RCTs found that supplementation with DHM significantly reduced the mean days of mechanical ventilation. Meta-analysis of 8 observational studies, which compared infants receiving MOM supplemented with DHM to infants receiving MOM supplemented with PF, showed a protective effect of DHM supplementation on BPD36 and on days of mechanical ventilation, but not on days on oxygen. Additionally, an exclusive HBM diet (i.e., MOM and/or DHM and DHM-derived

fortifier) significantly reduced the risk of BPD36, when compared to a diet that included PF and/or bovine milk-based fortifier. Feeding infants raw MOM, compared to feeding them pasteurized MOM, protected against BPD36. The authors concluded that the data analyzed suggest that DHM could protect against BPD in very preterm/VLBW infants. However, the process of pasteurization appeared to reduce the beneficial properties of HBM on BPD development.

Subsequently, two more systematic reviews^{99,100} were conducted and confirmed that the protective effects of HBM (MOM and/or DHM) on BPD are only observed in a meta-analysis of observational studies. Using the GRADE-system¹⁰¹, the authors of these meta-analyses consider the evidence to be inconclusive.

All these systematic reviews^{99,100} did not focus on the role of exclusive MOM vs. PF and did not study the effect of MOM separately from that of DHM.

Therefore, in 2019, Villamor-Martínez et al¹⁰² conducted a systematic review and meta-analysis on the association between MOM/PF feeding and BPD development, without including data on DHM. These authors identified 15 studies^{9,69,90,97,98,103-112} to include in the meta-analysis. Since the random allocation of infants to a group receiving PF instead of MOM is not ethical, these were only observational studies. The results of this meta-analysis showed that MOM reduced the risk of developing BPD but only when used as an exclusive diet. In contrast, a meta-analysis could not find significant changes in BPD risk when comparing infants fed mainly with MOM with those fed mainly with PF, or when comparing any MOM vs. exclusive PF. The protective effects of exclusive MOM were not affected by differences in gestational age. The results of the meta-analysis may indicate that the beneficial effects of exclusive MOM may be dose-dependent. Two previous case-control studies^{104,113}, not included in the meta-analysis, showed a reduction in BPD associated with increasing amounts of HBM. Fonseca et al¹⁰⁴ reported that a minimum amount of HBM (7 mL/kg/day) in the first 42 days was associated with a reduced incidence of BPD, and Patel et al¹¹³ have shown a 9.5% reduction in the risk of BPD for each 10% increase in MOM received from birth to 36 weeks PMA. This may generate a reduction in BPD risk up to 63% when an exclusive MOM diet is compared with an exclusive PF diet.

There may be various explanations for how the MOM acts in influencing the reduction in the incidence of BPD. In very preterm infants, BPD development is characterized by the arrest in the alveologenesi

and vasculogenesis of the lung. Other stimuli can act on the immature lung: prenatally, when chorioamnionitis occurs, the overwhelming inflammatory cascade may further interfere with lung development; postnatally, the intensive treatments needed add an inflammatory stimulus, leading to the establishment of BPD. Moreover, the incidence of BPD increases secondary to infections and inadequate nutrition. Based on these pathogenetic considerations, MOM can act thanks to nutritional and bioactive components, counteracting oxidative stress, inflammation, and nutritional flaws¹⁰². Moreover, MOM is involved in the reduction of NEC and late-onset sepsis risks that are related to the BPD risk themselves.

Although failure to thrive is a known risk factor for the development of BPD¹¹⁴, and lower weight gain is associated with an increased risk of BPD, this does not seem to apply to the reduced growth because of breastmilk feedings. This result emerged in the study of Spiegler et al¹⁸. These authors observed a reduced rate of BPD in the group of exclusively breastmilk-fed infants. As a consequence, also these authors concluded that they do not know whether more weight gain because of formula feeding compared with fortified breastmilk feeding during the neonatal course in the hospital is desirable or not¹⁸.

Recently, Yang et al¹¹⁵ published a review in which they examined the role of oxidative stress in the pathogenesis of BPD and the impact of antioxidants present in HBM on the prevention and treatment of BPD. HBM contains various antioxidants factors (glutathione, superoxide dismutase, glutathione peroxidase, short-chain fatty acids, unique HMOs, vitamins, phytochemicals, probiotics, melatonin, milk fat globule membrane) which could counteract the oxidative stress effects on normal lung development: hyperoxia causes poor lung development of the immature lungs of preterm infants, increases death of alveolar epithelial cells, and triggers pulmonary vascular remodeling. In the review, the authors examined several active compounds in HBM to define how they may ameliorate BPD oxidative stress in lung development. The mechanisms analyzed include: direct secretion of antioxidant substances able to clear free radicals and to prevent their accumulation; metal chelation; the enhancement of the antioxidant signaling pathway; the interaction with the intestinal flora; the inhibition of lipid peroxidation, and anti-inflammatory and anti-infection properties. Anyway, research about HBM antioxidants and their effects on BPD is still limited based on ethical factors and, as a consequence, only a few RCTs have been conducted. So, much research in this territory is required.

HBM and neurological outcomes

Inadequate nutrition during the critical period of brain development of preterm newborns could lead to neurocognitive impairments and permanently negative consequences⁴⁷. Premature newborns are particularly vulnerable compared to full-term newborns as they are exposed early to the external environment in a fundamental moment for brain development. In this context, nutritional factors, including HBM, have been identified as protective²³. Current evidence suggests that HBM is the best food for both term and preterm newborns conferring health benefits in short and long term. In particular, HBM feeding improves cognitive outcomes in preterm infants, possibly by directly protecting the preterm brain from injury and/or reducing adverse effects of injury on development¹¹⁶.

First, HBM intake is associated with a lower risk of neonatal infection and NEC which are common comorbidities among preterm infants during their hospital stay⁶⁷. These conditions can lead to systemic inflammation which, by activating the microglia in the central nervous system, can damage the oligodendrocytes and thus interfere with the development of the white matter. This has been associated with long-term changes in the brain microstructure and lower intelligence quotient⁶⁷. Ultimately, the positive effect of HBM on neurocognitive development could be partly explained by its preventive effect on the onset of infections and NEC.

Second, HBM contains bioactive components capable of acting directly on the development and protection of the central nervous system¹¹⁷. In particular, HBM is rich in long-chain polyunsaturated fatty acids (LC-PUFAs) which are normally synthesized from LA ω 6 and ALA ω 3, components found exclusively in HBM. These PUFAs are essential for brain development, as brain growth continues during the first weeks of life, especially for preterm infants, the intake of LA and ALA is fundamental⁴⁶. Moreover, HBM contains a high concentration of HMOs, which can be digested or undigested. The digestion of HMOs leads to the formation of monosaccharides, such as fucose and sialic acid, that are readily used in the synthesis of brain glycolipids, such as gangliosides, molecules of particular biological importance, which intervene in the maturation processes of the central nervous system⁴⁶. In addition, HBM contains other nutrients such as DHA, choline, and lactoferrin that play an essential role in normal brain development and are lacking in PF^{23,118}.

Third, the use of HBM as the main nutrient is a marker of a greater parent presence and engagement in the NICU. The bond itself between infant and parent, such as through skin-to-skin contact, is associated with better neurological outcomes^{23,119}.

However, HBM does not provide sufficient nutrition for the VLBW infants leading to slow growth with the risk of neurocognitive impairments. To prevent extrauterine growth retardation, associated with poor neurocognitive outcome, nutrient fortification of HBM is necessary, mostly concerning protein intake⁴⁷.

Finally, in the last decade brain magnetic resonance imaging (MRI) has been used to investigate the influence of BHM during a vulnerable period of rapid brain development in very preterm infants. A recent review²³ aimed to investigate the presence of typical brain MRI findings, such as punctate lesions in the white matter, altered microstructure, reduced volumes of several brain regions, and decreased cortical surface area in relation to the HBM feeding. The review revealed that, in the preterm population, exposure to HBM is associated with favorable brain development outcomes, including more mature and connected cerebral white matter, less volume of diffuse white matter abnormality, less dysmaturation across multiple brain regions, including deep nuclear gray matter, hippocampus, amygdala and cerebellum, and larger regional brain volumes²³.

SUPPORT BREASTFEEDING IN NICU

Breastfeeding, especially exclusive breastfeeding, is potentially important for promoting the health of both normal and low birthweight infants. The World Health Organization and the United Nations Children's Fund recommend and propel the policy of exclusively breastfeeding for the first 6 months of life^{120,121}.

The provision of breastfeeding support in the NICU may assist a mother to develop a milk supply for her preterm infant. HBM offers unique benefits to this highly vulnerable population. Breastfeeding influences actual supportive behaviors and provides more consistent messages to mothers during infant admission.

Feeding at the breast for preterm infants can be conceptualized as a series of steps, including: breast pump use at the infant's bedside; skin-to-skin holding; tasting HBM (suckling after breast pump use to remove all or some of the HBM); and finally consuming full feedings at the breast. There are no data to indicate that infants must attain a threshold weight or gestational age to begin tasting HBM, and several studies reveal that preterm infants remain more physiologically stable during breast than bottle feeding.

The maintenance of lactation, usually measured by whether the infant is still receiving partial or exclusive HBM at the time of NICU discharge, remains a

global problem with only a handful of best practices demonstrated to be effective.

All available evidence indicates that the NICU staff should prioritize the first 14 days post-birth, using proactive interventions to achieve maternal HBM volume. A NICU toolkit for managing these early lactation phases has been described and includes a user-friendly pumping diary (My Mom Pumps for Me!), the Coming to Volume Assessment Tool and a weekly maternal feeding goals interview tool (My Plans for Feeding my Baby at NICU discharge) that assures mothers' individual HBM feeding goals are monitored and supported¹²².

Lake et al¹²³ theorized that better NICU nursing characteristics, as measured by nurses' qualifications (education and years of experience), staffing level, and the nursing practice environment would result in improved breastfeeding support in the NICU, where the likely causal path was through better nursing care.

Lactation consultant (LC) availability across NICUs is not as well described in the literature; however, LCs dedicated to the NICU have been shown to improve both initiation and duration rates of breastfeeding in infants who have experienced an NICU stay.

Hallowell et al used regression models to examine the importance of 2 staffing variables, the PES-NWI subscale measure (staffing and resource adequacy) and the acuity-adjusted nurse-to-patient ratio, and found that both staffing variables were significantly associated with breastfeeding support, where better staffing was associated with a higher percentage of infants receiving breastfeeding support in the NICU.

The benefits of HBM have been well described; therefore, strategies to support the use of HBM and breastfeeding should be a priority. Exploration of the activities associated with breastfeeding support in the NICU as determined by nurses and mothers, such as communicating with mothers to develop an individualized feeding plan, assisting with direct breastfeeding or providing pump supplies, and evidence-based instruction, has been demonstrated to improve care and patient satisfaction¹²⁴.

A handful of multi-institutional quality initiatives have demonstrated higher rates of HBM provision at NICU discharge by adopting multidisciplinary infant nutrition and lactation teams that incorporate clear protocols for premature infants.

Most studies addressing barriers to the initiation and maintenance of lactation in mothers of preterm infants have focused primarily on motivational and behavioral interventions such as skin-to-skin care, patterns of breast pump use and models of support. However, many breast pump-dependent mothers of preterm

infants have chronic health problems or pregnancy and birth complications that impact lactation outcomes and that may be unresponsive to current behavioral and motivational interventions. These complications, which include, preterm birth, cesarean delivery and preeclampsia, as well as prolonged bed rest and medications to treat these complications, impact the hormonal processes that regulate secretory differentiation and early lactation. However, because preterm infants require so little HBM volume in the early post-birth period, these maternal HBM volume problems can easily go unrecognized for days or weeks, which impact lactation outcomes for breast pump-dependent mothers of preterm infants, who are often ill themselves¹¹⁹.

Another research priority is addressing the mothers' consistent reports about the dislike and inconvenience of breast pump use. Mothers of preterm infants are completely breast pump dependent, meaning that the breast pump regulates the lactation processes of HBM removal and mammary gland stimulation, which are critical to continued HBM production. Thus, a critical research priority for the maintenance of lactation in mothers of preterm infants is the improvement in the design of breast pumps and breast pump supplies so that they optimize efficiency and convenience, consistent with mothers' concerns.

CONCLUSIONS

Based on the current evidence, we can conclude that breastfeeding, thanks to the unique properties of HBM, may lead to several health benefits in preterm infants, including the improvement of neurodevelopmental outcomes. Further investigations are needed to understand the mechanisms and pathways underlying beneficial associations of HBM with neurodevelopmental outcomes, identifying specific HBM bioactive components with neuroprotective or neurorestorative potential. Exclusive MOM seems to reduce the risk of developing BPD and breastfeeding can ameliorate the effects of BPD. Anyway, to confirm the beneficial effects of MOM on BPD and to define the mechanisms implicated in the action of MOM in the pathogenesis of BPD, further studies are needed. These should be adequately powered to detect changes in BPD rates and adjusted for the different characteristics of infants who receive MOM and PF. Finally, HBM confers protection against NEC and infections, and decreases the overall mortality. For these reasons, promotion and support of HBM

feeding since the immediate post-delivery should be considered a priority in preterm infants' care.

Conflict of Interest

The authors declare that they have no conflict of interest.

REFERENCES

1. Eidelman AI. Breastfeeding and the use of human milk: an analysis of the American Academy of Pediatrics 2012 Breastfeeding Policy Statement. *Breastfeed Med*. 2012 Oct;7(5):323-324. doi: 10.1089/bfm.2012.0067.
2. Victora CG, Bahl R, Barros AJ, Franca GV, Horton S, Krasevec J, Murch S, Sankar MJ, Walker N, Rollins NC; Lancet Breastfeeding Series Group. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. *Lancet*. 2016 Jan 30;387(10017):475-490. doi: 10.1016/S0140-6736(15)01024-7.
3. Lönnerdal B. Bioactive Proteins in Human Milk-Potential Benefits for Preterm Infants. *Clin Perinatol*. 2017 Mar;44(1):179-191. doi: 10.1016/j.clp.2016.11.013.
4. Demmelmair H, Koletzko B. Lipids in human milk. *Best Pract Res Clin Endocrinol Metab*. 2018 Jan;32(1):57-68. doi: 10.1016/j.beem.2017.11.002.
5. Witkowska-Zimny M, Kaminska-El-Hassan E. Cells of human breast milk. *Cell Mol Biol Lett*. 2017 Jul 13;22:11. doi: 10.1186/s11658-017-0042-4.
6. Plaza-Díaz J, Fontana L, Gil A. Human Milk Oligosaccharides and Immune System Development. *Nutrients*. 2018 Aug;10(8):1038. doi: 10.3390/nu10081038.
7. McGuire MK, McGuire MA. Got bacteria? The astounding, yet not-so-surprising, microbiome of human milk. *Curr Opin Biotechnol*. 2017 Apr;44:63-68. doi: 10.1016/j.copbio.2016.11.013.
8. Lyons KE, Ryan CA, Dempsey EM, Ross RP, Stanton C. Breast Milk, a Source of Beneficial Microbes and Associated Benefits for Infant Health. *Nutrients*. 2020 Apr;12(4):1039. doi: 10.3390/nu12041039.
9. Schanler RJ, Lau C, Hurst NM, Smith EO. Randomized trial of donor human milk versus preterm formula as substitutes for mothers' own milk in the feeding of extremely premature infants. *Pediatrics*. 2005 Aug;116(2):400-406. doi: 10.1542/peds.2004-1974.
10. Meinen-Derr J, Poindexter B, Wrage L, Morrow AL, Stoll B, Donovan EF. Role of human milk in extremely low birth weight infants' risk of necrotizing enterocolitis or death. *J Perinatol*. 2009 Jan;29(1):57-62. doi: 10.1038/jp.2008.117.
11. Sullivan S, Schanler RJ, Kim JH, Patel AL, Trawöger R, Kiechl-Kohlendorfer U, Chan GM, Blanco

- CL, Abrams S, Cotten CM, Laroia N, Ehrenkranz RA, Dudell G, Cristofalo EA, Meier P, Lee ML, Rechtman DJ, Lucas A. An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products. *J Pediatr*. 2010 Apr;156(4):562-567.e1. doi: 10.1016/j.jpeds.2009.10.040.
12. Corpeleijn WE, Kouwenhoven SM, Paap MC, van Vliet I, Scheerder I, Muizer Y, Helder OK, van Goudoever JB, Vermeulen MJ. Intake of own mother's milk during the first days of life is associated with decreased morbidity and mortality in very low birth weight infants during the first 60 days of life. *Neonatology*. 2012;102(4):276-281. doi: 10.1159/000341335.
13. ESPGHAN Committee on Nutrition, Arslanoglu S, Corpeleijn W, Moro G, Braegger C, Campoy C, Colomb V, Decsi T, Domellöf M, Fewtrell M, Hojsak I, Mihatsch W, Mølgaard C, Shamir R, Turck D, van Goudoever J. Donor human milk for preterm infants: current evidence and research directions. *J Pediatr Gastroenterol Nutr*. 2013 Oct;57(4):535-542. doi: 10.1097/MPG.0b013e3182a3af0a.
14. Quigley M, Embleton ND, McGuire W. Formula versus donor breast milk for feeding preterm or low birth weight infants. *Cochrane Database Syst Rev*. 2018 Jun 20;6(6):CD002971. doi: 10.1002/14651858.CD002971.pub4. Update in: *Cochrane Database Syst Rev*. 2019 Jul 19;7:CD002971.
15. Manzoni P, Stolfi I, Pedicino R, Vagnarelli F, Mosca F, Pugni L, Bollani L, Pozzi M, Gomez K, Tzialla C, Borghesi A, Decembrino L, Mostert M, Latino MA, Priolo C, Galletto P, Gallo E, Rizzollo S, Tavella E, Luparia M, Corona G, Barberi I, Tridapalli E, Faldella G, Vetrano G, Memo L, Saia OS, Bordignon L, Messner H, Cattani S, Della Casa E, Laforgia N, Quercia M, Romeo M, Betta PM, Rinaldi M, Magaldi R, Maule M, Stronati M, Farina D; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, Italian Society of Neonatology. Human milk feeding prevents retinopathy of prematurity (ROP) in preterm VLBW neonates. *Early Hum Dev*. 2013 Jun;89 Suppl 1:S64-S68. doi: 10.1016/S0378-3782(13)70019-7.
16. Bharwani SK, Green BF, Pezzullo JC, Bharwani SS, Bharwani SS, Dhanireddy R. Systematic review and meta-analysis of human milk intake and retinopathy of prematurity: a significant update. *J Perinatol*. 2016 Nov;36(11):913-920. doi: 10.1038/jp.2016.98.
17. Dani C, Coviello C, Panin F, Frosini S, Costa S, Purcaro V, Lepore D, Vento G. Incidence and risk factors of retinopathy of prematurity in an Italian cohort of preterm infants. *Ital J Pediatr*. 2021 Mar;47(1):64. doi: 10.1186/s13052-021-01011-w.
18. Spiegler J, Preuß M, Gebauer C, Bendiks M, Herting E, Göpel W; German Neonatal Network (GNN); German Neonatal Network GNN. Does Breastmilk Influence the Development of Bronchopulmonary Dysplasia? *J Pediatr*. 2016 Feb;169:76-80.e4. doi: 10.1016/j.jpeds.2015.10.080.
19. Dicky O, Ehlinger V, Montjaux N, Gremmo-Féger G, Sizun J, Rozé JC, Arnaud C, Casper C; EPIPAGE 2 Nutrition Study Group; EPINUTRI Study Group. Policy of feeding very preterm infants with their mother's own fresh expressed milk was associated with a reduced risk of bronchopulmonary dysplasia. *Acta Paediatr*. 2017 May;106(5):755-762. doi: 10.1111/apa.13757.
20. Serrao F, Papacci P, Costa S, Giannantonio C, Cota F, Vento G, Romagnoli C. Effect of Early Expressed Human Milk on Insulin-Like Growth Factor 1 and Short-Term Outcomes in Preterm Infants. *PLoS One*. 2016 Dec;11(12):e0168139. doi: 10.1371/journal.pone.0168139.
21. Rozé JC, Darmaun D, Boquien CY, Flamant C, Picaud JC, Savagner C, Claris O, Lapillonne A, Mitanchez D, Branger B, Simeoni U, Kaminski M, Ancel PY. The apparent breastfeeding paradox in very preterm infants: relationship between breast feeding, early weight gain and neurodevelopment based on results from two cohorts, EPIPAGE and LIFT. *BMJ Open*. 2012 Apr;2(2):e000834. doi: 10.1136/bmjopen-2012-000834.
22. Lechner BE, Vohr BR. Neurodevelopmental Outcomes of Preterm Infants Fed Human Milk: A Systematic Review. *Clin Perinatol*. 2017 Mar; 44(1): 69-83. doi: 10.1016/j.clp.2016.11.004.
23. Belfort MB, Knight E, Chandarana S, Ikem E, Gould JF, Collins CT, Makrides M, Gibson RA, Anderson PJ, Simmer K, Tiemeier H, Rumbold A. Associations of Maternal Milk Feeding With Neurodevelopmental Outcomes at 7 Years of Age in Former Preterm Infants. *JAMA Netw Open*. 2022 Jul;5(7):e2221608. doi: 10.1001/jamanetworkopen.2022.21608.
24. Rito AI, Buoncristiano M, Spinelli A, Salanave B, Kunešová M, Hejgaard T, García Solano M, Fijałkowska A, Sturua L, Hyska J, Kelleher C, Duleva V, Musić Milanović S, Farrugia Sant'Angelo V, Abdrakhmanova S, Kujundzic E, Peterkova V, Gualtieri A, Pudule I, Petrauskienė A, Tanrygulyyeva M, Sherali R, Huidumac-Petrescu C, Williams J, Ahrens W, Breda J. Association between Characteristics at Birth, Breastfeeding and Obesity in 22 Countries: The WHO European Childhood Obesity Surveillance Initiative – COSI 2015/2017. *Obes Facts*. 2019;12(2):226-243. doi: 10.1159/000500425.

25. Lind MV, Larnkjær A, Mølgaard C, Michaelsen KF. Breastfeeding, Breast Milk Composition, and Growth Outcomes. *Nestle Nutr Inst Workshop Ser.* 2018;89:63-77. doi: 10.1159/000486493.
26. Kim SY, Yi DY. Components of human breast milk: from macronutrient to microbiome and microRNA. *Clin Exp Pediatr.* 2020 Aug;63(8):301-309. doi: 10.3345/cep.2020.00059.
27. Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors. *Pediatr Clin North Am.* 2013 Feb;60(1):49-74. doi: 10.1016/j.pcl.2012.10.002.
28. Martin CR, Ling PR, Blackburn GL. Review of Infant Feeding: Key Features of Breast Milk and Infant Formula. *Nutrients.* 2016 May 11;8(5):279. doi: 10.3390/nu8050279.
29. Underwood MA. Human milk for the premature infant. *Pediatr Clin North Am.* 2013 Feb;60(1):189-207. doi: 10.1016/j.pcl.2012.09.008.
30. Kunz C, Rodriguez-Palmero M, Koletzko B, Jensen R. Nutritional and biochemical properties of human milk, Part I: General aspects, proteins, and carbohydrates. *Clin Perinatol.* 1999 Jun;26(2):307-333.
31. Hester SN, Hustead DS, Mackey AD, Singhal A, Marriage BJ. Is the macronutrient intake of formula-fed infants greater than breast-fed infants in early infancy? *J Nutr Metab.* 2012;2012:891201. doi: 10.1155/2012/891201.
32. Thurl S, Munzert M, Boehm G, Matthews C, Stahl B. Systematic review of the concentrations of oligosaccharides in human milk. *Nutr Rev.* 2017 Nov;75(11):920-933. doi: 10.1093/nutrit/nux044.
33. Ward RE, Niñonuevo M, Mills DA, Lebrilla CB, German JB. In vitro fermentation of breast milk oligosaccharides by *Bifidobacterium infantis* and *Lactobacillus gasseri*. *Appl Environ Microbiol.* 2006 Jun;72(6):4497-4499. doi: 10.1128/AEM.02515-05.
34. Newburg DS, Walker WA. Protection of the neonate by the innate immune system of developing gut and of human milk. *Pediatr Res.* 2007 Jan;61(1):2-8. doi: 10.1203/01.pdr.0000250274.68571.18.
35. Morrow AL, Ruiz-Palacios GM, Altaye M, Jiang X, Guerrero ML, Meinen-Derr JK, Farkas T, Chaturvedi P, Pickering LK, Newburg DS. Human milk oligosaccharide blood group epitopes and innate immune protection against campylobacter and calicivirus diarrhea in breastfed infants. *Adv Exp Med Biol.* 2004;554:443-446. doi: 10.1007/978-1-4757-4242-8_61.
36. Guo M. Human milk biochemistry and infant formula manufacturing technology. Elsevier, 2nd Edition 2020.
37. Lönnerdal B, Lien EL. Nutritional and physiologic significance of alpha-lactalbumin in infants. *Nutr Rev.* 2003 Sep;61(9):295-305. doi: 10.1301/nr.2003.sept.295-305.
38. Donovan SM, Lönnerdal B. Non-protein nitrogen and true protein in infant formulas. *Acta Paediatr Scand.* 1989 Jul;78(4):497-504. doi: 10.1111/j.1651-2227.1989.tb17927.x.
39. Koletzko B, Rodriguez-Palmero M, Demmelmair H, Fidler N, Jensen R, Sauerwald T. Physiological aspects of human milk lipids. *Early Hum Dev.* 2001 Nov;65 Suppl:S3-S18. doi: 10.1016/s0378-3782(01)00204-3.
40. Ip S, Chung M, Raman G, Chew P, Magula N, DeVine D, Trikalinos T, Lau J. Breastfeeding and maternal and infant health outcomes in developed countries. *Evid Rep Technol Assess (Full Rep).* 2007 Apr;(153):1-186.
41. Donohoe DR, Garge N, Zhang X, Sun W, O'Connell TM, Bunker MK, Bultman SJ. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. *Cell Metab.* 2011 May;13(5):517-526. doi: 10.1016/j.cmet.2011.02.018.
42. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. *J Nutr.* 2009 Sep;139(9):1619-1625. doi: 10.3945/jn.109.104638.
43. Tanaka K, Hosozawa M, Kudo N, Yoshikawa N, Hisata K, Shoji H, Shinohara K, Shimizu T. The pilot study: sphingomyelin-fortified milk has a positive association with the neurobehavioural development of very low birth weight infants during infancy, randomized control trial. *Brain Dev.* 2013 Jan;35(1):45-52. doi: 10.1016/j.braindev.2012.03.004.
44. Dror DK, Allen LH. Overview of Nutrients in Human Milk. *Adv Nutr.* 2018 May;9(suppl_1):278S-294S. doi: 10.1093/advances/nmy022.
45. Wiechers C, Bernhard W, Goelz R, Poets CF, Franz AR. Optimizing Early Neonatal Nutrition and Dietary Pattern in Premature Infants. *Int J Environ Res Public Health.* 2021 Jul;18(14):7544. doi: 10.3390/ijerph18147544.
46. Boquien CY. Human Milk: An Ideal Food for Nutrition of Preterm Newborn. *Front Pediatr.* 2018 Oct;6:295. doi: 10.3389/fped.2018.00295.
47. Arslanoglu S, Boquien CY, King C, Lamireau D, Tonetto P, Barnett D, Bertino E, Gaya A, Gebauer C, Grovslén A, Moro GE, Weaver G, Wesolowska AM, Picaud JC. Fortification of Human Milk for Preterm Infants: Update and Recommendations of the European Milk Bank Association (EMBA) Working Group on Human Milk Fortification. *Front Pediatr.* 2019 Mar;7:76. doi: 10.3389/fped.2019.00076.
48. Sinha B, Dudeja N, Chowdhury R, Choudhary TS, Upadhyay RP, Rongsen-Chandola T, Mazumder S, Taneja S, Bhandari N. Enteral Zinc Supplementation in Preterm or Low Birth Weight Infants: A Systematic

- Review and Meta-analysis. *Pediatrics*. 2022 Aug;150(Suppl 1):e2022057092J. doi: 10.1542/peds.2022-057092J.
49. Field CJ. The immunological components of human milk and their effect on immune development in infants. *J Nutr*. 2005 Jan;135(1):1-4. doi: 10.1093/jn/135.1.1.
50. Thai JD, Gregory KE. Bioactive Factors in Human Breast Milk Attenuate Intestinal Inflammation during Early Life. *Nutrients*. 2020 Feb;12(2):581. doi: 10.3390/nu12020581.
51. Burge K, Vieira F, Eckert J, Chaaban H. Lipid Composition, Digestion, and Absorption Differences among Neonatal Feeding Strategies: Potential Implications for Intestinal Inflammation in Preterm Infants. *Nutrients*. 2021 Feb;13(2):550. doi: 10.3390/nu13020550.
52. Ledo A, Arduini A, Asensi MA, Sastre J, Escrig R, Brugada M, Aguar M, Saenz P, Vento M. Human milk enhances antioxidant defenses against hydroxyl radical aggression in preterm infants. *Am J Clin Nutr*. 2009 Jan;89(1):210-215. doi: 10.3945/ajcn.2008.26845.
53. Perrone S, Salvi G, Bellieni CV, Buonocore G. Oxidative stress and nutrition in the preterm newborn. *J Pediatr Gastroenterol Nutr*. 2007 Dec;45 Suppl 3:S178-182. doi: 10.1097/01.mpg.0000302968.83244.d2. Erratum in: *J Pediatr Gastroenterol Nutr*. 2009 Jan;48(1):121-122.
54. York DJ, Smazal AL, Robinson DT, De Plaen IG. Human Milk Growth Factors and Their Role in NEC Prevention: A Narrative Review. *Nutrients*. 2021 Oct;13(11):3751. doi: 10.3390/nu13113751.
55. Ghosh A. Breast Milk Stem Cell Survival in Neonate's Gut, Entry into Neonate Circulation and Adaption by the Body. *Curr Stem Cell Res Ther*. 2020;15(2):98-101. doi: 10.2174/1574888X14666191107095728.
56. Bardanzellu F, Peroni DG, Fanos V. Human Breast Milk: Bioactive Components, from Stem Cells to Health Outcomes. *Curr Nutr Rep*. 2020 Mar;9(1):1-13. doi: 10.1007/s13668-020-00303-7.
57. Scott H, Sweet L, Strauch L, Muller A. Expressed breastmilk handling and storage guidelines available to mothers in the community: a scoping review. *Women Birth*. 2020 Sep;33(5):426-432. doi: 10.1016/j.wombi.2019.09.009.
58. Moro GE, Arslanoglu S, Bertino E, Corvaglia L, Montirosso R, Picaud JC, Polberger S, Schanler RJ, Steel C, van Goudoever J, Ziegler EE; American Academy of Pediatrics; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. XII. Human Milk in Feeding Premature Infants: Consensus Statement. *J Pediatr Gastroenterol Nutr*. 2015 Sep;61 Suppl 1:S16-19. doi: 10.1097/01.mpg.0000471460.08792.4d.
59. Moro GE, Arslanoglu S. Heat treatment of human milk. *J Pediatr Gastroenterol Nutr*. 2012 Feb;54(2):165-166. doi: 10.1097/MPG.0b013e318235d629.
60. Haiden N, Ziegler EE. Human Milk Banking. *Ann Nutr Metab*. 2016;69 Suppl 2:8-15. doi: 10.1159/000452821.
61. Adamkin DH. Use of human milk and fortification in the NICU. *J Perinatol*. 2022 Oct 18. doi: 10.1038/s41372-022-01532-0. Online ahead of print.
62. Rochow N, Fusch G, Choi A, Chessell L, Elliott L, McDonald K, Kuiper E, Purcha M, Turner S, Chan E, Xia MY, Fusch C. Target fortification of breast milk with fat, protein, and carbohydrates for preterm infants. *J Pediatr*. 2013 Oct;163(4):1001-1007. doi: 10.1016/j.jpeds.2013.04.052.
63. Rochow N, Fusch G, Ali A, Bhatia A, So HY, Iskander R, Chessell L, El Helou S, Fusch C. Individualized target fortification of breast milk with protein, carbohydrates, and fat for preterm infants: A double-blind randomized controlled trial. *Clin Nutr*. 2021 Jan;40(1):54-63. doi: 10.1016/j.clnu.2020.04.031.
64. Arslanoglu S, Bertino E, Coscia A, Tonetto P, Giuliani F, Moro GE. Update of adjustable fortification regimen for preterm infants: a new protocol. *J Biol Regul Homeost Agents*. 2012 Jul-Sep;26(3 Suppl):65-67.
65. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, Higgins RD; National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. *JAMA*. 2004 Nov;292(19):2357-2365. doi: 10.1001/jama.292.19.2357.
66. Patel RM. Short- and Long-Term Outcomes for Extremely Preterm Infants. *Am J Perinatol*. 2016 Feb;33(3):318-328. doi: 10.1055/s-0035-1571202.
67. Lapidaire W, Lucas A, Clayden JD, Clark C, Fewtrell MS. Human milk feeding and cognitive outcome in preterm infants: the role of infection and NEC reduction. *Pediatr Res*. 2022 Apr;91(5):1207-1214. doi: 10.1038/s41390-021-01367-z.
68. Meister AL, Doheny KK, Travagli RA. Necrotizing enterocolitis: It's not all in the gut. *Exp Biol Med* (Maywood). 2020 Jan;245(2):85-95. doi: 10.1177/1535370219891971.
69. Cortez J, Makker K, Kraemer DF, Neu J, Sharma R, Hudak ML. Maternal milk feedings reduce sepsis, necrotizing enterocolitis and improve outcomes of premature infants. *J Perinatol*. 2018 Jan;38(1):71-74. doi: 10.1038/jp.2017.149.
70. Fitzstevens JL, Smith KC, Hagadorn JI, Caimano MJ, Matson AP, Brownell EA. Systematic Review of the Human Milk Microbiota. *Nutr Clin Pract*. 2017 Jun;32(3):354-364. doi: 10.1177/0884533616670150.

71. Embleton ND, Berrington JE, Dorling J, Ewer AK, Juszczak E, Kirby JA, Lamb CA, Lanyon CV, McGuire W, Probert CS, Rushton SP, Shirley MD, Stewart CJ, Cummings SP. Mechanisms Affecting the Gut of Preterm Infants in Enteral Feeding Trials. *Front Nutr*. 2017 May;4:14. doi: 10.3389/fnut.2017.00014.
72. Nolan LS, Rimer JM, Good M. The Role of Human Milk Oligosaccharides and Probiotics on the Neonatal Microbiome and Risk of Necrotizing Enterocolitis: A Narrative Review. *Nutrients*. 2020 Oct;12(10):3052. doi: 10.3390/nu12103052.
73. Newburg DS, He Y. Neonatal Gut Microbiota and Human Milk Glycans Cooperate to Attenuate Infection and Inflammation. *Clin Obstet Gynecol*. 2015 Dec;58(4):814-826. doi: 10.1097/GRF.0000000000000156.
74. Donald K, Petersen C, Turvey SE, Finlay BB, Azad MB. Secretory IgA: linking microbes, maternal health, and infant health through human milk. *Cell Host Microbe*. 2022 May;30(5):650-659. doi: 10.1016/j.chom.2022.02.005.
75. Anghel L, Radulescu A, Erhan RV. Structural aspects of human lactoferrin in the iron-binding process studied by molecular dynamics and small-angle neutron scattering. *Eur Phys J E Soft Matter*. 2018 Sep;41(9):109. doi: 10.1140/epje/i2018-11720-x. Erratum in: *Eur Phys J E Soft Matter*. 2018 Nov;41(11):133.
76. ELFIN trial investigators group. Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial. *Lancet*. 2019 Feb;393(10170):423-433. doi: 10.1016/S0140-6736(18)32221-9.
77. Resch B. How to Provide Breast Milk for the Preterm Infant and Avoid Symptomatic Cytomegalovirus Infection with Possible Long-Term Sequelae. *Life (Basel)*. 2022 Mar;12(4):504. doi: 10.3390/life12040504.
78. Wiggins JB, Trotman R, Perks PH, Swanson JR. Enteral Nutrition: The Intricacies of Human Milk from the Immune System to the Microbiome. *Clin Perinatol*. 2022 Jun;49(2):427-445. doi: 10.1016/j.clp.2022.02.009.
79. Slomski A. Human Milk Protein Prevents Infections in Preterm Infants. *JAMA*. 2016 Nov;316(20):2078. doi: 10.1001/jama.2016.17037.
80. Siffel C, Kistler KD, Lewis JFM, Sarda SP. Global incidence of bronchopulmonary dysplasia among extremely preterm infants: a systematic literature review. *J Matern Fetal Neonatal Med*. 2021 Jun;34(11):1721-1731. doi: 10.1080/14767058.2019.1646240.
81. McEvoy CT, Jain L, Schmidt B, Abman S, Bancalari E, Aschner JL. Bronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. *Ann Am Thorac Soc*. 2014 Apr;11 Suppl 3(Suppl 3):S146-153. doi: 10.1513/AnnalsATS.201312-424LD.
82. Wemhöner A, Ortner D, Tschirch E, Strasak A, Rüdiger M. Nutrition of preterm infants in relation to bronchopulmonary dysplasia. *BMC Pulm Med*. 2011 Feb;11:7. doi: 10.1186/1471-2466-11-7.
83. Villamor-Martínez E, Pierro M, Cavallaro G, Mosca F, Kramer BW, Villamor E. Donor Human Milk Protects against Bronchopulmonary Dysplasia: A Systematic Review and Meta-Analysis. *Nutrients*. 2018 Feb;10(2):238. doi: 10.3390/nu10020238.
84. Corpeleijn WE, de Waard M, Christmann V, van Goudoever JB, Jansen-van der Weide MC, Kooi EM, Koper JF, Kouwenhoven SM, Lafeber HN, Mank E, van Toledo L, Vermeulen MJ, van Vliet I, van Zoeren-Grobbe D. Effect of Donor Milk on Severe Infections and Mortality in Very Low-Birth-Weight Infants: The Early Nutrition Study Randomized Clinical Trial. *JAMA Pediatr*. 2016 Jul;170(7):654-661. doi: 10.1001/jamapediatrics.2016.0183.
85. Cossey V, Vanhole C, Eerdeken A, Rayyan M, Fieuws S, Schuermans A. Pasteurization of mother's own milk for preterm infants does not reduce the incidence of late-onset sepsis. *Neonatology*. 2013;103(3):170-176. doi: 10.1159/000345419.
86. Omarsdottir S, Casper C, Navér L, Legnevall L, Gustafsson F, Grillner L, Zweyberg-Wirgart B, Söderberg-Nauclér C, Vanpée M. Cytomegalovirus infection and neonatal outcome in extremely preterm infants after freezing of maternal milk. *Pediatr Infect Dis J*. 2015 May;34(5):482-489. doi: 10.1097/INF.0000000000000619.
87. O'Connor DL, Gibbins S, Kiss A, Bando N, Brennan-Donnan J, Ng E, Campbell DM, Vaz S, Fusch C, Asztalos E, Church P, Kelly E, Ly L, Daneman A, Unger S; GTA DoMINO Feeding Group. Effect of Supplemental Donor Human Milk Compared With Preterm Formula on Neurodevelopment of Very Low-Birth-Weight Infants at 18 Months: A Randomized Clinical Trial. *JAMA*. 2016 Nov;316(18):1897-1905. doi: 10.1001/jama.2016.16144.
88. Cristofalo EA, Schanler RJ, Blanco CL, Sullivan S, Trawöeger R, Kiechl-Kohlendorfer U, Dudell G, Rechtman DJ, Lee ML, Lucas A, Abrams S. Randomized trial of exclusive human milk versus preterm formula diets in extremely premature infants. *J Pediatr*. 2013 Dec;163(6):1592-1595.e1. doi: 10.1016/j.jpeds.2013.07.011.
89. Hanson C, Lyden E, Furtado J, Van Ormer M, Anderson-Berry A. A Comparison of Nutritional Antioxidant Content in Breast Milk, Donor Milk, and Infant Formulas. *Nutrients*. 2016 Oct;8(11):681. doi: 10.3390/nu8110681.
90. Assad M, Elliott MJ, Abraham JH. Decreased cost and improved feeding tolerance in VLBW infants

- fed an exclusive human milk diet. *J Perinatol*. 2016 Mar;36(3):216-220. doi: 10.1038/jp.2015.168.
91. Colacci M, Murthy K, DeRegnier RO, Khan JY, Robinson DT. Growth and Development in Extremely Low Birth Weight Infants After the Introduction of Exclusive Human Milk Feedings. *Am J Perinatol*. 2017 Jan;34(2):130-137. doi: 10.1055/s-0036-1584520.
 92. Ginovart G, Gich I, Verd S. Human milk feeding protects very low-birth-weight infants from retinopathy of prematurity: a pre-post cohort analysis. *J Matern Fetal Neonatal Med*. 2016 Dec;29(23):3790-3795. doi: 10.3109/14767058.2016.1145648.
 93. Giuliani F, Prandi G, Coscia A, Cresi F, Di Nicola P, Raia M, Sabatino G, Occhi L, Bertino E. Donor human milk versus mother's own milk in preterm VLBWIs: a case control study. *J Biol Regul Homeost Agents*. 2012 Jul-Sep;26(3 Suppl):19-24.
 94. Hair AB, Peluso AM, Hawthorne KM, Perez J, Smith DP, Khan JY, O'Donnell A, Powers RJ, Lee ML, Abrams SA. Beyond Necrotizing Enterocolitis Prevention: Improving Outcomes with an Exclusive Human Milk-Based Diet. *Breastfeed Med*. 2016 Mar;11(2):70-74. doi: 10.1089/bfm.2015.0134. Erratum in: *Breastfeed Med*. 2017 Dec;12(10):663.
 95. Kreissl A, Sauerzapf E, Repa A, Binder C, Thanhaeuser M, Jilma B, Ristl R, Berger A, Haiden N. Starting enteral nutrition with preterm single donor milk instead of formula affects time to full enteral feeding in very low birthweight infants. *Acta Paediatr*. 2017 Sep;106(9):1460-1467. doi: 10.1111/apa.13914.
 96. Lee SH, Park JH, Kim CS, Lee SL. Clinical findings according to feeding diets in very low birth weight infants: human breast milk versus bovine milk-based formula. *Neonat Med*. 2016;23:23-28.
 97. Sisk PM, Lambeth TM, Rojas MA, Lightbourne T, Barahona M, Anthony E, Auringer ST. Necrotizing Enterocolitis and Growth in Preterm Infants Fed Predominantly Maternal Milk, Pasteurized Donor Milk, or Preterm Formula: A Retrospective Study. *Am J Perinatol*. 2017 Jun;34(7):676-683. doi: 10.1055/s-0036-1597326.
 98. Madore LS, Bora S, Erdei C, Jumani T, Dengos AR, Sen S. Effects of Donor Breastmilk Feeding on Growth and Early Neurodevelopmental Outcomes in Preterm Infants: An Observational Study. *Clin Ther*. 2017 Jun;39(6):1210-1220. doi: 10.1016/j.clinthera.2017.05.341.
 99. Huang J, Zhang L, Tang J, Shi J, Qu Y, Xiong T, Mu D. Human milk as a protective factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. *Arch Dis Child Fetal Neonatal Ed*. 2019 Mar;104(2):F128-F136. doi: 10.1136/archdischild-2017-314205.
 100. Miller J, Tonkin E, Damarell RA, McPhee AJ, Sukanuma M, Sukanuma H, Middleton PF, Makrides M, Collins CT. A Systematic Review and Meta-Analysis of Human Milk Feeding and Morbidity in Very Low Birth Weight Infants. *Nutrients*. 2018 May;10(6):707. doi: 10.3390/nu10060707.
 101. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008 Apr;336(7650):924-926. doi: 10.1136/bmj.39489.470347.AD.
 102. Villamor-Martínez E, Pierro M, Cavallaro G, Mosca F, Villamor E. Mother's Own Milk and Bronchopulmonary Dysplasia: A Systematic Review and Meta-Analysis. *Front Pediatr*. 2019 Jun;7:224. doi: 10.3389/fped.2019.00224.
 103. Fewtrell MS, Morley R, Abbott RA, Singhal A, Isaacs EB, Stephenson T, MacFadyen U, Lucas A. Double-blind, randomized trial of long-chain polyunsaturated fatty acid supplementation in formula fed to preterm infants. *Pediatrics*. 2002 Jul;110(1 Pt 1):73-82. doi: 10.1542/peds.110.1.73.
 104. Fonseca LT, Senna DC, Silveira RC, Procianny RS. Association between Breast Milk and Bronchopulmonary Dysplasia: A Single Center Observational Study. *Am J Perinatol*. 2017 Feb;34(3):264-269. doi: 10.1055/s-0036-1586503.
 105. Furman L, Taylor G, Minich N, Hack M. The effect of maternal milk on neonatal morbidity of very low-birth-weight infants. *Arch Pediatr Adolesc Med*. 2003 Jan;157(1):66-71. doi: 10.1001/archpedi.157.1.66.
 106. Hylander MA, Strobino DM, Dhanireddy R. Human milk feedings and infection among very low birth weight infants. *Pediatrics*. 1998 Sep;102(3):E38. doi: 10.1542/peds.102.3.e38.
 107. Jacobi-Polishook T, Collins CT, Sullivan TR, Simmer K, Gillman MW, Gibson RA, Makrides M, Belfort MB. Human milk intake in preterm infants and neurodevelopment at 18 months corrected age. *Pediatr Res*. 2016 Oct;80(4):486-492. doi: 10.1038/pr.2016.114.
 108. Maayan-Metzger A, Avivi S, Schushan-Eisen I, Kuint J. Human milk versus formula feeding among preterm infants: short-term outcomes. *Am J Perinatol*. 2012 Feb;29(2):121-126. doi: 10.1055/s-0031-1295652.
 109. O'Connor DL, Jacobs J, Hall R, Adamkin D, Auestad N, Castillo M, Connor WE, Connor SL, Fitzgerald K, Groh-Wargo S, Hartmann EE, Janowsky J, Lucas A, Margeson D, Mena P, Neuringer M, Ross G, Singer L, Stephenson T, Szabo J, Zemon V. Growth and development of premature infants fed predominantly human milk, predominantly premature infant formula, or a combination of human milk and premature formula. *J Pediatr Gastroenterol Nutr*. 2003 Oct;37(4):437-446. doi: 10.1097/00005176-200310000-00008.

110. Patra K, Hamilton M, Johnson TJ, Greene M, Dabrowski E, Meier PP, Patel AL. NICU Human Milk Dose and 20-Month Neurodevelopmental Outcome in Very Low Birth Weight Infants. *Neonatology*. 2017;112(4):330-336. doi: 10.1159/000475834.
111. Sisk PM, Lovelady CA, Dillard RG, Gruber KJ, O'Shea TM. Early human milk feeding is associated with a lower risk of necrotizing enterocolitis in very low birth weight infants. *J Perinatol*. 2007 Jul;27(7):428-433. doi: 10.1038/sj.jp.7211758. Erratum in: *J Perinatol*. 2007 Dec;27(12):808.
112. Vohr BR, Poindexter BB, Dusick AM, McKinley LT, Wright LL, Langer JC, Poole WK; NICHD Neonatal Research Network. Beneficial effects of breast milk in the neonatal intensive care unit on the developmental outcome of extremely low birth weight infants at 18 months of age. *Pediatrics*. 2006 Jul;118(1):e115-23. doi: 10.1542/peds.2005-2382.
113. Patel AL, Johnson TJ, Robin B, Bigger HR, Buchanan A, Christian E, Nandhan V, Shroff A, Schoeny M, Engstrom JL, Meier PP. Influence of own mother's milk on bronchopulmonary dysplasia and costs. *Arch Dis Child Fetal Neonatal Ed*. 2017 May;102(3):F256-F261. doi: 10.1136/archdischild-2016-310898.
114. Biniwale MA, Ehrenkranz RA. The role of nutrition in the prevention and management of bronchopulmonary dysplasia. *Semin Perinatol*. 2006 Aug;30(4):200-208. doi: 10.1053/j.semperi.2006.05.007.
115. Yang X, Jiang S, Deng X, Luo Z, Chen A, Yu R. Effects of Antioxidants in Human Milk on Bronchopulmonary Dysplasia Prevention and Treatment: A Review. *Front Nutr*. 2022 Jul;9:924036. doi: 10.3389/fnut.2022.924036.
116. Cerasani J, Ceroni F, De Cosmi V, Mazzocchi A, Morniroli D, Roggero P, Mosca F, Agostoni C, Gianni ML. Human Milk Feeding and Preterm Infants' Growth and Body Composition: A Literature Review. *Nutrients*. 2020 Apr;12(4):1155. doi: 10.3390/nu12041155.
117. Beverly RL, Huston RK, Markell AM, McCulley EA, Martin RL, Dallas DC. Differences in human milk peptide release along the gastrointestinal tract between preterm and term infants. *Clin Nutr*. 2021 Mar;40(3):1214-1223. doi: 10.1016/j.clnu.2020.07.035.
118. Lockyer F, McCann S, Moore SE. Breast Milk Micronutrients and Infant Neurodevelopmental Outcomes: A Systematic Review. *Nutrients*. 2021 Oct;13(11):3848. doi: 10.3390/nu13113848.
119. Meier PP, Johnson TJ, Patel AL, Rossman B. Evidence-Based Methods That Promote Human Milk Feeding of Preterm Infants: An Expert Review. *Clin Perinatol*. 2017 Mar;44(1):1-22. doi: 10.1016/j.clp.2016.11.005.
120. https://www.who.int/health-topics/breastfeeding#tab=tab_2
121. <https://www.unicef.org/press-releases/who-unicef-issue-new-guidance-promote-breastfeeding-globally>
122. Meier PP, Patel AL, Bigger HR, Rossman B, Engstrom JL. Supporting breastfeeding in the neonatal intensive care unit: Rush Mother's Milk Club as a case study of evidence-based care. *Pediatr Clin North Am*. 2013 Feb;60(1):209-226. doi: 10.1016/j.pcl.2012.10.007.
123. Lake ET, Staiger D, Horbar J, Cheung R, Kenny MJ, Patrick T, Rogowski JA. Association between hospital recognition for nursing excellence and outcomes of very low-birth-weight infants. *JAMA*. 2012 Apr;307(16):1709-1716. doi: 10.1001/jama.2012.504.
124. Hallowell SG, Spatz DL, Hanlon AL, Rogowski JA, Lake ET. Characteristics of the NICU work environment associated with breastfeeding support. *Adv Neonatal Care*. 2014 Aug;14(4):290-300. doi: 10.1097/ANC.0000000000000102.